Regulation - Merck & Co, Anti-Arthritics/Rheumatics

Filter

Popular Filters

Merck & Co closes odanacatib trial early on good results in osteoporosis

13-07-2012

US drug giant Merck & Co (NYSE: MRK) says it is halting a Phase III trial of its investigational osteoporosis…

Anti-Arthritics/RheumaticsMerck & CoodanacatibPharmaceuticalRegulationResearch

Merck & Co highlights pipeline progress; plans eight US filings in 2012-

11-11-2011

US pharma giant Merck & Co (NYSE:MRK) hosted an upbeat R&D and Business Briefing yesterday, where it…

Anti-Arthritics/RheumaticsBridonCardio-vascularFinancialMerck & CoNeurologicalodanacatibOncologyPharmaceuticalRegulationResearchsuvorexantTredaptive

Parexel

Parexel

Back to top